RBC Recommends Buying Sarepta (SRPT) on Weakness Related to UnitedHealthcare Commercial Drug Policy

December 1, 2016 11:02 AM EST Send to a Friend
RBC Capital analyst Simos Simeonidis weighed in on Sarepta Therapeutic (NASDAQ: SRPT) saying he believes UnitedHealthcare Commercial Drug Policy on ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login